Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Homatropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.92 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.92 |
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 0.92 |
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.92 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.92 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.54 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | BLM | P54132 | 2/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.92 |
| ▸ | HTR2C | P28335 | 3/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | HRH1 | P35367 | 2/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homatropine SCHEMBL14672464 | 1.00 | LMNA (0.95) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL23970 | 0.97 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL9653008 | 0.97 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL15275620 | 0.97 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL23969 | 0.97 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL23468168 | 0.97 | LMNA (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL41951 | 0.96 | CHRM2 (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL220965 | 0.96 | LMNA (0.97) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL41950 | 0.96 | CHRM2 (1.00) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Homatropine SCHEMBL220964 | 0.96 | LMNA (0.97) | LMNACYP2D6CYP2C9HSD17B10CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-9556200-B2 | Tricyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9504266-B2 | Photodegradable gum base, a chewing gum comprising the photodegradable gum base and methods of making the same | INTERCONTINENTAL GREAT BRANDS LLC (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2824106-B1 | TRICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-3043653-A1 | CHEWING GUM COMPOSITION COMPRISING A MICRO-ENCAPSULATED FLAVOUR IN A MATRIX COMPRISING PROTEIN | Intercontinental Great Brands LLC (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160192674-A1 | CHEWING GUM COMPOSITION COMPRISING A MICRO-ENCAPSULATED FLAVOUR IN A MATRIX COMPRISING PROTEIN | INTERCONTINENTAL GREAT BRANDS LLC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160095331-A1 | COLORED WAX COMPOSITIONS | INTERCONTINENTAL GREAT BRANDS LLC (US) | 2016-04-07 | — | — | US | disclosed |
| EP-2991504-A1 | COLORED WAX COMPOSITIONS | Intercontinental Great Brands LLC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20150264958-A1 | CHEWING GUM PRODUCT AND METHOD FOR THE FORMATION THEREOF | INTERCONTINENTAL GREAT BRANDS LLC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-2018863-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| EP-1910292-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007089031-A1 | PIPERIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| WO-2007015588-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | WO | disclosed |
| EP-1705176-A1 | CARBOXAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | CHRM2 292/4885CHRM1 386/4885CHRM3 297/4885 |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | CHRM2 356/4885CHRM1 345/4885CHRM3 320/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | CHRM2 251/4885CHRM1 219/4885CHRM3 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.